Feasibility assessment of in vitro chemoresponse assay on stereotactic biopsies of glioblastoma multiforms: a step towards personalized medicine

• Main Authors: Fariba Sadeghi Fazel, Mahnaz Haddadi, Alireza Khoshnevisan, Samad Muhammadnejad, Ahad Muhammadnejad, Zohreh Mazaheri, Motahareh Arjomandnejad, Reza Shirkoohi, Mohammad-Ali Oghabian, Narjes Sherkat-Khameneh, Saeid Amanpour, Monireh Kazemimanesh
• Format: Article
• Language: English
• Published: Mashhad University of Medical Sciences 2014-11-01
• Series: Iranian Journal of Basic Medical Sciences
• Subjects: Glioblastomamultiform In vitro chemosensitivity and resistance assay Personalized medicine Primary explant technique Stereotactic biopsy
• Online Access: http://ijbms.mums.ac.ir/pdf_3747_18889a2b2c356f4ab92fad027b03e2be.html
• ISSN: 2008-3866; 2008-3874

Objective(s):P In vitro chemosensitivity and resistance assays (CSRAs) are a promising tool for personalized treatment of glioblastoma multiform (GBM). These assays require a minimum of 1 to 2 g of tumor specimen for testing, but this amount is not always accessible. We aimed to assess the feasibility and validity of utilizing stereotactic biopsies of GBM in CSRAs. Materials and Methods: Single cell suspension was prepared from 1 g weight explants of the established xenograft tumor of GBM. Also, primary culture was carried out on 35 mg weight specimens, as a surrogate for stereotactic biopsies. Then, chemoresponse profile of cells obtained by direct cell disaggregation and primary culture was determined using temozolomide and carmustine by clonogenic assay[AGA1] . Results: There was no statistically significant difference in the cytotoxicity of temozolomide and carmustine between cells obtained from both methods. Conclusion: This work supports the feasibility of using stereotactic biopsies of GBM in CSRAs.